Skip to main content
ENTX
NASDAQ Life Sciences

FDA Gives Positive Feedback on Entera Bio's Phase 3 Protocol for Oral Osteoporosis Drug EB613

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.328
Mkt Cap
$59.641M
52W Low
$0.91
52W High
$3.22
52W Position info
46% above low
Off High info
59% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

ENTX sits 46% above its 52-week low of $0.91 on light trading volume (0.3× avg).

Summary

Entera Bio received positive FDA feedback on the protocol for its 12-month registrational Phase 3 study of EB613, an oral anabolic tablet for postmenopausal osteoporosis. The FDA accepted the proposed single, randomized, placebo-controlled trial design in approximately 750 patients, with a primary endpoint of total hip bone mineral density at 12 months. This provides a clear and optimized regulatory path for the company's lead product candidate, significantly de-risking its development. This clarity is crucial for a small biotech, especially following recent capital raises and shareholder requests for increased authorized shares to fund its pipeline. Phase 3 initiation is planned for late 2026, with topline data expected in the second half of 2028.

At the time of this announcement, ENTX was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.6M. The 52-week trading range was $0.91 to $3.22. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ENTX - Latest Insights

ENTX
Oct 14, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $2.52
Real-time Price: $2.90 info
Change: +$0.380 (+15%) info
Market Cap: $525.896M info
ENTX
Oct 13, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.60
Real-time Price: $2.90 info
Change: +$0.300 (+12%) info
Market Cap: $525.896M info
ENTX
Sep 23, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $2.81
Real-time Price: $2.90 info
Change: +$0.090 (+3%) info
Market Cap: $525.896M info
ENTX
Aug 28, 2026, 4:13 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $3.03
Real-time Price: $2.90 info
Change: -$0.130 (-4%) info
Market Cap: $525.896M info
ENTX
Aug 07, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.85
Real-time Price: $2.90 info
Change: +$0.050 (+2%) info
Market Cap: $525.896M info